[ad_1]
Oslo, Norway, June 22, 2021 /PRNewswire/ – Targovax ASA (OSE: TRVX) is a clinical-stage immuno-oncology company that develops immune activators to target difficult-to-treat solid tumors. Today, it announced that its main clinical candidate drug ONCOS-102 has achieved rapid PD-1 refractory late stage The channel designates melanoma from the US FDA.
The US FDA has granted ONCOS-102 Fast Track designation based on current preclinical and clinical data packages, including evidence of the mechanism showing the association between ONCOS-102-induced immune activation and tumor response. Obtaining this designation is the US FDA’s recognition of the strength and importance of ONCOS-102 data packet in PD-1 refractory advanced melanoma. This fast-track approval is a supplement to ONCOS-102’s existing fast-track designation for malignant pleural diseases…
The full story on Benzinga.com
[ad_2]
Source link
